LifeSci Capital analyst Charles Zhu has maintained their bullish stance on IDYA stock, giving a Buy rating on July 22.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Charles Zhu has given his Buy rating due to a combination of factors, primarily focusing on the promising potential of IDEAYA Biosciences’ IDE849, a DLL3-targeted ADC. The upcoming clinical data presentation at the WCLC 2025 Conference is expected to showcase IDE849’s active profile, which has already shown promise in dose escalation data and is supported by external validation from other DLL3-directed therapies.
Despite some investor concerns regarding the licensing deal for IDE849 and the competitive landscape of SCLC, Zhu highlights the strategic positioning of IDEAYA relative to competitors like ZL-1310. IDEAYA’s management emphasizes the unique linker of IDE849, which could potentially allow for higher dosing and improved response rates, particularly in later-line SCLC patients. This, combined with IDEAYA’s history of successful business development and translation of early insights into clinical validation, underpins Zhu’s confidence in the stock’s potential upside.